دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Dyslipidemia in Chronic Kidney Disease: Contemporary Concepts and Future Therapeutic Perspectives
Theofilis P. · Vordoni A. · Koukoulaki M. · Vlachopanos G. · Kalaitzidis R.G.
doi : 10.1159/000518456
Am J Nephrol 2021;52:693–701
Chronic kidney disease (CKD) is an increasingly prevalent disease state met with great morbidity and mortality primarily resulting from the high incidence of adverse cardiovascular outcomes. Therapeutic strategies in this patient population aim at controlling modifiable cardiovascular risk factors, including dyslipidemia.
Factors Affecting Doses of Roxadustat Versus Darbepoetin Alfa for Anemia in Nondialysis Patients
Akizawa T.a · Tanaka-Amino K.b · Otsuka T.c · Yamaguchi Y.d
doi : 10.1159/000519043
Am J Nephrol 2021;52:702–713
Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor for treating anemia of chronic kidney disease (CKD). This post hoc analysis of a Japanese, open-label, partially randomized, phase 3 study in nondialysis-dependent (NDD) CKD patients treated with traditional erythropoiesis-stimulating agents (ESAs) evaluated dosing trends of roxadustat and darbepoetin alfa (DA) required to maintain target hemoglobin concentrations in patients with risk factors associated with ESA hyporesponsiveness.
Urinary Plasminogen Activator Inhibitor-1: A Biomarker of Acute Tubular Injury
Paniagua-Sancho M.a,b,c · Quiros Y.a,c,d · Casanova A.G.a,b,c · Blanco-Gozalo V.a,b,c · Agüeros-Blanco C.e · Benito-Hernández A.e · Ramos-Barron M.A.e · Gómez-Alamillo C.e · Arias M.e · Sancho-Martínez S.M.a,b,c,f,g · López-Hernández F.J.a,b,c,d,f,g
doi : 10.1159/000518455
Am J Nephrol 2021;52:714–724
Acute kidney injury (AKI) is a threatening, multiaetiological syndrome encompassing a variety of forms and damage patterns. AKI lacks sufficiently specific diagnostic tools to evaluate the distinct combination of pathophysiological events underlying each case, which limits personalized and optimized handling. Therefore, a pathophysiological diagnosis based on new urinary biomarkers is sought for practical (readiness and noninvasiveness) and conceptual reasons, as the urine is a direct product of the kidneys. However, biomarkers found in the urine may also have extrarenal origin, thus conveying pathophysiological information from other organs or tissues. Urinary plasminogen activator inhibitor-1 (PAI-1) has been associated to AKI, although its origin and traffic to the urine are not known.
C-X-C Motif Chemokine Ligand 16 Is a Potent Predictor of Outcomes in Dialysis Patients
Liu W.a · Wang L.b · Li X.c · Gao C.d · Zhou J.d · Zhou J.d · Wang L.e · Sun Z.e · Chu H.f · Fan W.f · Bai Y.g · Yang J.b
doi : 10.1159/000518400
Am J Nephrol 2021;52:725–734
C-X-C motif chemokine ligand 16 (CXCL16) is an inflammatory marker that has been found to be predictive of outcomes in patients with cardiovascular disease. Our previous work has also demonstrated its relation to cardiac injury in dialysis patients. However, it is yet unclear whether there is an association between CXCL16 and adverse outcomes in dialysis patients. We aimed to evaluate its prognostic value along with several traditional inflammatory markers in the current study.
Impact of Polypharmacy on Health-Related Quality of Life in Dialysis Patients
Colombijn J.M.T.a · Bonenkamp A.A.a · van Eck van der Sluijs A.b · Bijlsma J.A.a,c · Boonstra A.H.d · Özyilmaz A.e,f · Abrahams A.C.b · van Jaarsveld B.C.a,g · on behalf of the DOMESTICO study group
doi : 10.1159/000518454
Am J Nephrol 2021;52:735–744
Dialysis patients are often prescribed a large number of medications to improve metabolic control and manage coexisting comorbidities. However, some studies suggest that a large number of medications could also detrimentally affect patients’ health-related quality of life (HRQoL). Therefore, this study aims to provide insight in the association between the number of types of medications and HRQoL in dialysis patients.
IL-6 Is Associated with Progression of Coronary Artery Calcification and Mortality in Incident Dialysis Patients
Roy N.a,b · Rosas S.E.a,b
doi : 10.1159/000518652
Am J Nephrol 2021;52:745–752
Inflammation is important in the pathogenesis of atherosclerosis. Elevated interleukin-6 (IL-6) is associated with cardiovascular events and also predicts mortality in individuals with CKD. Our goal was to determine the association between IL-6, FGF23, and high-sensitivity C-reactive protein (hsCRP) on coronary artery calcification (CAC) progression and mortality in incident dialysis patients without prior coronary events.
Estimation of Baseline Serum Creatinine with Machine Learning
Ghosh E.a · Eshelman L.a · Lanius S.a · Schwager E.a · Pasupathy K.S.b · Barreto E.F.c · Kashani K.d,e
doi : 10.1159/000518902
Am J Nephrol 2021;52:753–762
Comparing current to baseline serum creatinine is important in detecting acute kidney injury. In this study, we report a regression-based machine learning model to predict baseline serum creatinine.
The Combined Prognostic Significance of Alkaline Phosphatase and Intracranial Arterial Calcifications in Hemodialysis Patients
Erez D.a · Fanadka F.b · Benchetrit S.c,d · Cohen-Hagai K.c,d
doi : 10.1159/000518399
Am J Nephrol 2021;52:763–769
The prevalence of intracranial arterial calcification (ICAC) in maintenance hemodialysis (MHD) patients is about 90%, and its severity is correlated with age, hemodialysis vintage, and mineral bone disease. Elevated concentrations of calcium and phosphorus are not sufficient for medial calcification because of inhibition by pyrophosphate. Alkaline phosphatase (ALP) promotes calcification by hydrolyzing extracellular pyrophosphate. Epigenetic mechanisms involving ALP inhibition by apabetalone were investigated as a potential target for preventing vascular calcifications (VCs). This study assessed the combined impact of VCs and elevated serum ALP on mortality among chronic HD patients.
